Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

Aspergillus species have emerged as an important cause of life-threatening infections in immunocompromised patients. This expanding population is composed of patients with prolonged neutropenia, advanced HIV infection, and inherited immunodeficiency and patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT) and/or lung transplantation. This document constitutes the guidelines of the Infectious Diseases Society of America for treatment of aspergillosis and replaces the practice guidelines for Aspergillus published in 2000 The objective of these

• A
  Amgen
• P
  Pfizer
• AP
  Astellas Pharma US
• GS
  Gilead Sciences
• C
  Celgene
• EP
  Enzon Pharmaceuticals
• WT
  Wellcome Trust
• AP
  Astellas Pharma